全文获取类型
| 收费全文 | 105959篇 |
| 免费 | 6841篇 |
| 国内免费 | 876篇 |
专业分类
| 耳鼻咽喉 | 1231篇 |
| 儿科学 | 3144篇 |
| 妇产科学 | 2598篇 |
| 基础医学 | 13990篇 |
| 口腔科学 | 2582篇 |
| 临床医学 | 8537篇 |
| 内科学 | 23592篇 |
| 皮肤病学 | 2214篇 |
| 神经病学 | 9992篇 |
| 特种医学 | 4337篇 |
| 外国民族医学 | 23篇 |
| 外科学 | 15581篇 |
| 综合类 | 1674篇 |
| 一般理论 | 52篇 |
| 预防医学 | 5671篇 |
| 眼科学 | 1660篇 |
| 药学 | 8290篇 |
| 3篇 | |
| 中国医学 | 521篇 |
| 肿瘤学 | 7984篇 |
出版年
| 2023年 | 508篇 |
| 2022年 | 525篇 |
| 2021年 | 2299篇 |
| 2020年 | 1443篇 |
| 2019年 | 2028篇 |
| 2018年 | 2488篇 |
| 2017年 | 1924篇 |
| 2016年 | 2017篇 |
| 2015年 | 2347篇 |
| 2014年 | 3013篇 |
| 2013年 | 4310篇 |
| 2012年 | 5858篇 |
| 2011年 | 6015篇 |
| 2010年 | 3834篇 |
| 2009年 | 3389篇 |
| 2008年 | 5259篇 |
| 2007年 | 5360篇 |
| 2006年 | 5036篇 |
| 2005年 | 4827篇 |
| 2004年 | 5048篇 |
| 2003年 | 4850篇 |
| 2002年 | 4896篇 |
| 2001年 | 3813篇 |
| 2000年 | 3767篇 |
| 1999年 | 3062篇 |
| 1998年 | 1202篇 |
| 1997年 | 947篇 |
| 1996年 | 879篇 |
| 1995年 | 846篇 |
| 1994年 | 725篇 |
| 1993年 | 698篇 |
| 1992年 | 1829篇 |
| 1991年 | 1797篇 |
| 1990年 | 1526篇 |
| 1989年 | 1471篇 |
| 1988年 | 1353篇 |
| 1987年 | 1202篇 |
| 1986年 | 1182篇 |
| 1985年 | 1050篇 |
| 1984年 | 769篇 |
| 1983年 | 705篇 |
| 1982年 | 453篇 |
| 1981年 | 383篇 |
| 1979年 | 582篇 |
| 1978年 | 427篇 |
| 1975年 | 434篇 |
| 1974年 | 487篇 |
| 1973年 | 463篇 |
| 1972年 | 428篇 |
| 1971年 | 394篇 |
排序方式： 共有10000条查询结果，搜索用时 15 毫秒
21.
22.
23.
24.
25.
26.
27.
28.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献29.
30.
Although hepatitis E virus (HEV) is the primary cause of enterically transmitted acute hepatitis and jaundice in developing countries, locally acquired HEV infections are increasing in nonendemic countries. As such, HEV is emerging as an underdiagnosed cause of infection. This report describes three clinically variable cases of HEV infection with unusual clinical presentations. These cases highlight the fact that HEV should be considered in the differential diagnosis of patients with unexplained hepatitis (acute or chronic) with or without extrahepatic manifestations. HEV should also be considered in patients with persistently elevated liver enzymes who have not travelled to known HEV-endemic regions. Lack of knowledge among physicians and an absence of standardized diagnostic tests may result in increased morbidity and mortality from HEV infection. 相似文献